Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early CNS Prophylaxis in High-Risk DLBCL
NCT03719560Phase 2Withdrawn
- Sponsor
- Brown University
- Start
- Jul 2019
- Primary completion
- Dec 2022
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of methotrexate and cytarabine in diffuse large B-cell lymphoma (DLBCL), sponsored by Brown University. Primary endpoint: Proportion with clinically significant toxicity at 1 year. Planned start Jul 2019; status: withdrawn.
02
Drugs
methotrexatecytarabine
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT03719560.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03719560.